Skip to content
OpenCapital
Get started

Kopin KOPN Research And Development Funded

Research And Development Funded at other companies

AMP
Amphastar PharmaceuticalsAMPH
$2.5M+2,400%
Babcock & Wilcox Enterprises logo
Babcock & Wilcox EnterprisesBW
$803K+131%
Adient logo
AdientADNT
$72M+2.9%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$57.07M+12.2%
Cabot Corporation logo
Cabot CorporationCBT
$14M-6.7%
Belden logo
BeldenBDC
$30.09M+5.9%

Other financials

Income statement

See full
Revenue$10.6M+0.1%
Operating income-$6.0M-53.2%
Net income-$3.8M-20.5%
EPS (diluted)-$0.020.0%

Balance sheet

See full
Cash & equivalents$34.1M+123%
Total debt$1.3M-31.7%
Total equity$60.8M+194%
Total assets$102.4M+57.5%

Cash flow

See full
Operating cash flow-$810.7K+76.3%
CapEx$1.3M+160%
Free cash flow-$2.1M+46.0%

Valuation

See full
Market cap$702.29M+175%
Enterprise value$669.47M+177%
P/E356.9×—
P/S17.9×+12.8×

Profitability

See full
Gross margin46.7%—
Operating margin-30.3%+2.4pp
Net margin5%+2.7pp
FCF margin-38.6%+13.3pp

Returns & leverage

See full
Return on equity4.8%+2.5pp
Debt / equity0×-0.1×
Current ratio2.6×+1.2×

Where this comes from

Reported directly by Kopin in its filing.

Tagged under the XBRL concept KOPN:ResearchAndDevelopmentFunded.

The official record: Kopin’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kopin's research and development funded.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kopin's research and development funded?
Kopin (KOPN) reported research and development funded of $3.81M in Q1 2026.
How has Kopin's research and development funded changed year-over-year?
Kopin's research and development funded increased by 495.9% year-over-year, from $638.72K to $3.81M.
What does research and development funded mean?
Refers to research and development activities that are specifically financed by third-party contracts or government grants rather than internal capital. This metric highlights the company's ability to leverage external partnerships to advance its technological capabilities while mitigating internal financial risk. It serves as an indicator of the company's relevance and strategic importance to its primary customers.